Twelve years of experience of breast cancer at the Institut Curie: improvement of survival and value of screening mammographics

Salmon, R; Asselain, Bernard; Gal, M. Le

doi:10.1016/s0960-9776(97)90574-9

Cited by 8 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The data, including treatments, were entered prospectively into the Institute's BC database set up in 1981 (Salmon et al, 1997). Chemotherapy regimens in adjuvant and neoadjuvant setting varied over time based on CMF (cyclophosphamide, methotrexate and 5-fluorouracile), FAC (5-fluorouracile, adriamycine and cyclophosphamide) or FEC (epirubicin).…”

Section: Methodsmentioning

confidence: 99%

Second malignancies after breast cancer: the impact of different treatment modalities

et al. 2008

View full text Add to dashboard Cite

Treatment for non-metastatic breast cancer (BC) may be the cause of second malignancies in long-term survivors. Our aim was to investigate whether survivors present a higher risk of malignancy than the general population according to treatment received. We analysed data for 16 705 BC survivors treated at the Curie Institute (1981 -1997) by either chemotherapy (various regimens), radiotherapy (high-energy photons from a 60 Co unit or linear accelerator) and/or hormone therapy (2 -5 years of tamoxifen). We calculated age-standardized incidence ratios (SIRs) for each malignancy, using data for the general French population from five regional registries. At a median follow-up 10.5 years, 709 patients had developed a second malignancy. The greatest increases in risk were for leukaemia (SIR: 2.07 (1.52 -2.75)), ovarian cancer (SIR: 1.6 (1.27 -2.04)) and gynaecological (cervical/endometrial) cancer (SIR: 1.6 (1.34 -1.89); Po0.0001). The SIR for gastrointestinal cancer, the most common malignancy, was 0.82 (0.70 -0.95; Po0.007). The increase in leukaemia was most strongly related to chemotherapy and that in gynaecological cancers to hormone therapy. Radiotherapy alone also had a significant, although lesser, effect on leukaemia and gynaecological cancer incidence. The increased risk of sarcomas and lung cancer was attributed to radiotherapy. No increased risk was observed for malignant melanoma, lymphoma, genitourinary, thyroid or head and neck cancer. There is a significantly increased risk of several kinds of second malignancy in women treated for BC, compared with the general population. This increase may be related to adjuvant treatment in some cases. However, the absolute risk is small. The overall survival rate of patients with early advanced breast cancer (BC) has increased over the years largely because adjuvant therapy, whether chemotherapy, radiotherapy or hormone therapy, has helped prevent local and distant failures (Fox, 1979;Jones and Raghavan, 1993; EBCTCG, 2005). Second malignancies that occur in long-term survivors may be due to sporadic cancers that would have occurred anyway, environmental or genetic factors (Klijn et al, 1997;Schrag et al, 1997;Turner et al, 1999;Meijers-Heijboer et al, 2000;Pierce et al, 2000Pierce et al, , 2003 StoppaLyonnet et al, 2000;Galper et al, 2002;Kauff et al, 2002;Pierce, 2002;Robson, 2002;Seynaeve et al, 2004; Kirova et al, 2005aKirova et al, , b, 2006aLaki et al, 2007), or BC treatment (Neugut et al, 1993;Inskip et al, 1994;Ahsan and Neugut, 1998;Karlsson et al, 1998;Kirova et al, 1998 Kirova et al, , 2005aKirova et al, , b, 2007Obedian et al, 2000;Rubino et al, 2000;Scholl et al, 2001;Shousha et al 2001;Yap et al, 2002 Yap et al, , 2005Deutsch et al, 2003;Zablotska and Neugut, 2003;Zablotska et al, 2005;Mellemkjaer et al, 2006) The aim of this study was to estimate the risk of a second malignancy after adjuvant treatment for BC in a homogeneous cohort of patients from a single institution. The observed incidence of second malignancies in these BC patients was com...

show abstract

Section: Methodsmentioning

confidence: 99%

Second malignancies after breast cancer: the impact of different treatment modalities

et al. 2008

View full text Add to dashboard Cite

show abstract

“…One control had to be excluded because it did not meet our selection criteria, giving a total of 261 sporadic cases (271 breast tumours). Controls were randomly selected from our prospective breast cancer registry of 9179 patients who underwent conservative treatment between 1981 and 2000, as reported earlier [28,46]. Matching factors included age at diagnosis, year of treatment, and period of follow-up between cases and controls.…”

Section: Patientsmentioning

confidence: 99%

Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature

Kirova

Savignoni

Sigal‐Zafrani

et al. 2009

Breast Cancer Res Treat

View full text Add to dashboard Cite

As tumours in BRCA1/2 mutation carriers might be more sensitive to radiation, we investigated after long-term follow-up whether mutation status influenced the rate of ipsilateral and contralateral breast cancers after breast-conserving treatment (BCT). BRCA1 and BRCA2 genes were screened for germline mutations in 131 patients with a family history of breast and/or ovarian cancer who had undergone BCT and radiotherapy. Patients were matched to 261 controls with sporadic breast cancer according to age at diagnosis and year of treatment. Controls were followed up for at least as long as the interval between diagnosis and genetic screening in familial cases. Rates of ipsilateral and contralateral cancer between groups were compared by the log-rank test. The BRCA1/2 mutations occurred in 20.6% of tested patients. Tumours in mutation carriers were more likely to be grade III (P < 10(-4)) and oestrogen receptor negative (P = 0.005) than in non-carriers and controls. Overall median follow-up was 161 months. There was no significant difference in ipsilateral tumours between mutation carriers, non-carriers and controls (P = 0.13). On multivariate analysis, age was the most significant predictor for ipsilateral recurrence (P < 10(-3)). The rate of contralateral cancer was significantly higher in familial cases: 40.7% (mutation carriers), 20% (non-carriers), and 11% (controls) (P < 10(-4)). After 13.4 years of follow-up, the rate of ipsilateral tumours was no higher in mutation carriers than in non-carriers or controls. As tumours in BRCA1/2 mutation carriers might be more sensitive to radiation, BCT is a possible treatment option.

show abstract

The Global and Regional Survival Rate of Women With Breast Cancer: A Systematic Review and Meta-analysis

Maajani

Jalali

Alipour

et al. 2019

Clinical Breast Cancer

124

View full text Add to dashboard Cite

Twelve years of experience of breast cancer at the Institut Curie: improvement of survival and value of screening mammographics

Cited by 8 publications

References 9 publications

Second malignancies after breast cancer: the impact of different treatment modalities

Second malignancies after breast cancer: the impact of different treatment modalities

Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature

The Global and Regional Survival Rate of Women With Breast Cancer: A Systematic Review and Meta-analysis

Contact Info

Product

Resources

About